Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,233,177
  • Shares Outstanding, K 93,255
  • Annual Sales, $ 788,090 K
  • Annual Income, $ 37,010 K
  • 60-Month Beta 1.24
  • Price/Sales 11.42
  • Price/Cash Flow 141.56
  • Price/Book 10.75
Trade NBIX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.16
  • Number of Estimates 12
  • High Estimate 0.96
  • Low Estimate -0.65
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -79.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.26 +5.04%
on 10/02/20
105.47 -6.12%
on 10/12/20
-0.36 (-0.36%)
since 09/23/20
3-Month
94.26 +5.04%
on 10/02/20
127.19 -22.16%
on 07/24/20
-29.14 (-22.74%)
since 07/23/20
52-Week
72.14 +37.25%
on 03/18/20
136.26 -27.34%
on 07/09/20
+1.48 (+1.52%)
since 10/23/19

Most Recent Stories

More News
New Strong Sell Stocks for October 19th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

DAL : 34.00 (+0.83%)
NBIX : 99.01 (+2.57%)
CBL : 0.1666 (+0.30%)
SKY : 27.09 (+4.59%)
CUB : 60.80 (-0.31%)
New Strong Sell Stocks for October 16th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

OGE : 33.16 (+2.06%)
DAL : 34.00 (+0.83%)
NBIX : 99.01 (+2.57%)
PTSI : 48.86 (+1.14%)
CHRA : 3.05 (+2.35%)
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients...

NBIX : 99.01 (+2.57%)
XENE : 10.72 (+2.49%)
Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments™, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic

and , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and -based Me2/Orchestra, the world's only known classical music organization created for people with mental illness and the people that...

NBIX : 99.01 (+2.57%)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on . Neurocrine will then host a conference...

NBIX : 99.01 (+2.57%)
Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyses evaluating the efficacy and safety of ONGENTYS (opicapone) capsules, recently approved by the...

NBIX : 99.01 (+2.57%)
Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that 50 mg capsules of ONGENTYS (opicapone), the first and only FDA-approved once-daily catechol-O-methyltransferase (COMT)...

NBIX : 99.01 (+2.57%)
Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily ONGENTYS (opicapone) capsules decreased...

NBIX : 99.01 (+2.57%)
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease

and , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from  PD-1101, a Phase Ib open-label, three-year efficacy and safety...

NBIX : 99.01 (+2.57%)
VYGR : 11.03 (+0.09%)
Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18 Annual Global Healthcare Conference at 1:30 p.m. ET on . , Chief Executive Officer, and , Chief Financial...

MS : 51.87 (+0.19%)
NBIX : 99.01 (+2.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

2nd Resistance Point 100.96
1st Resistance Point 99.99
Last Price 99.01
1st Support Level 97.21
2nd Support Level 95.41

See More

52-Week High 136.26
Fibonacci 61.8% 111.77
Fibonacci 50% 104.20
Last Price 99.01
Fibonacci 38.2% 96.64
52-Week Low 72.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar